MT-200605

MICOT 点击蓝字 关注我们 Slide to view different languages 滑动查看不同语言 近日，陕西麦科奥特医药科技股份有限公司（麦科医药，2335.HK）作为“心脑血管栓塞性疾病防治创新药物研发及临床试验”项目主要参与单位，向创新药物研发国家科技重大专项项目组正式汇报了其自主研发的注射用神经保护候选药物MT200605的任务执行情况及后续临床开发计划。MT200605自入选国家科技重大专项以来，各项研究工作稳步推进，III期确证性临床研究正加速落地，承载着改变卒中治疗现状的期待。 以“两弹一星”精神攻克国民健康难关 如果说“两弹一星”是捍卫国家安全的战略基石，那么创新药物研发国家科技重大专项就是守卫人民生命健康的“国之重器”——它瞄准的是国民最急迫、最严重的健康威胁，目标是攻克药品可及性与临床疗效的“卡脖子”难题。 麦科医药CMO王湘玲在汇报MT200605 脑卒中是国人致死致残的头号病因，每年新发患者超过300万，且呈现年轻化趋势。数十年来，神经保护剂领域屡遭挫折，大量在研药物在临床试验阶段折戟，始终未能转化为确切的患者获益，临床需求远未被满足。MT200605正是直面这一重大临床需求的原研创新药，其II期临床已读出确切的疗效信号。 以突破性临床证据锚定III期确证方向 MT200605能够获得创新药物研发国家科技重大专项的认可与支持，凭借的是其独特的机制优势和明确的临床转化潜力。 01 神经保护方向 II期研究严格遵循国际监管机构广泛认可的功能学恢复终点开展评估，在小样本量下即观察到试验组较安慰剂组呈现明确且稳健的临床获益，疗效信号清晰、方向一致，为后续大规模确证性研究奠定了坚实基础。MT200605同时也是目前全球唯一能够穿过血脑屏障、在人体上完成临床疗效验证的TrkB受体激动剂，其“主动促进修复”的作用机制在卒中神经保护领域具有开创性意义。 02 肾保护方向 MT200605展现出显著的差异化优势。卒中患者中急性肾损伤（AKI）发生率高达12%-19%，现有神经保护剂普遍携带肾损伤风险，或肾受损者需慎用。II期研究中，MT200605在肾脏保护维度上表现出积极信号，凸显了其“脑肾双保护”的独特潜力，有望为卒中后AKI这一尚无特异性预防手段的临床难题提供全新解决方案。 高质量推进III期临床，不负国家使命 CMO 王湘玲 “MT200605能够入选国家科技重大专项，是对我们多年深耕创新药研发的充分肯定，更是对卒中患者的一份沉甸甸的责任。麦科医药将不遗余力集中最优资源，确保III期临床高质量、高效率推进。我们深知，这款药物承载着无数患者和家庭的期待，唯有以最严谨的科学态度和最严格的执行标准，才能不负这份信任与使命。” 根据汇报方案，MT200605的III期研究为多中心、随机、双盲、安慰剂对照确证性临床试验，计划在全国约90家中心入组1036例急性缺血性卒中患者，以第90天mRS 0-1分为主要终点，由首都医科大学附属北京天坛医院院长王拥军院士担任主要研究者。作为全球首创的小分子TrkB受体激动剂，MT200605若能在III期复制II期的获益幅度，将有机会成为国内卒中神经保护领域首个具有改变临床实践潜力的一线治疗产品，为卒中后AKI特异性预防提供首个解决方案。 MICOT Recently, Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot Pharma, 2335.HK), a major participant in the project “Innovative Drug Development and Clinical Trials for the Prevention and Treatment of Cardiovascular and Cerebrovascular Thrombotic Diseases,” formally reported to the National Science and Technology Major Project for Innovative Drug Development team on progress with its injectable neuroprotective candidate MT200605 and its clinical development plan. Since its inclusion in the National Science and Technology Major Project, MT200605 has progressed steadily, while its Phase III confirmatory trial is accelerating, with the potential to reshape stroke treatment. Tackling Major National Health Challenges in the Spirit of “Two Bombs, One Satellite” If the “Two Bombs, One Satellite” program was a cornerstone of national security, the National Science and Technology Major Project for Innovative Drug Development is a strategic pillar safeguarding public health. It targets the most urgent and serious health threats facing the Chinese population, aiming to overcome key bottlenecks in drug accessibility and clinical efficacy. Wang Xiangling, CMO of Micot Pharma, Reporting about MT200605 Stroke is the leading cause of death and disability in China, with more than 3 million new cases annually and an increasing trend among younger patients. For decades, neuroprotective drug development has faced repeated setbacks, with numerous investigational agents failing in clinical trials and unable to deliver clear patient benefit, leaving major clinical needs unmet. MT200605 is an original innovative drug developed to address this major unmet need, and its Phase II trial has shown a clear efficacy signal. Defining the Phase III Confirmatory Path with Breakthrough Clinical Evidence MT200605 received recognition and support from the National Science and Technology Major Project for Innovative Drug Development for its unique mechanism and clear clinical translation potential. 01 Neuroprotection The Phase II study rigorously assessed functional recovery using endpoints widely accepted by international regulators. Despite the small sample size, the treatment group showed clear, robust benefit versus placebo, with a consistent efficacy signal, supporting subsequent large-scale confirmatory studies. MT200605 is also the world’s only TrkB receptor agonist that crosses the blood–brain barrier and has demonstrated clinical efficacy in humans. Its “active repair” mechanism is pioneering in stroke neuroprotection. 02 Renal Protection MT200605 has shown clear differentiation. AKI occurs in 12%–19% of stroke patients, while existing neuroprotective agents commonly carry renal injury risks or require caution in renal impairment. In Phase II, MT200605 showed a positive renal safety signal, highlighting its unique dual brain–kidney protection potential and offering a new potential solution for post-stroke AKI, which currently lacks specific prevention. Advancing Phase III to High Standards in Fulfillment of a National Mission CMO 王湘玲 “The inclusion of MT200605 in the National Science and Technology Major Project is strong recognition of our years of innovative drug R&D and, more importantly, a profound responsibility to stroke patients. Micot will spare no effort to concentrate its best resources and ensure high-quality, efficient advancement of the Phase III trial. We fully recognize the expectations that countless patients and families place on this drug. Only with the most rigorous scientific approach and strictest execution standards can we live up to this trust and responsibility.” According to the plan presented, the Phase III study of MT200605 will be a multicenter, randomized, double-blind, placebo-controlled confirmatory trial, enrolling 1,036 patients with acute ischemic stroke at about 90 sites across China. The primary endpoint will be mRS 0–1 at Day 90. Professor Yongjun Wang, Member of the Chinese Academy of Sciences and President of Beijing Tiantan Hospital, Capital Medical University, will serve as principal investigator. As a global first-in-class small-molecule TrkB receptor agonist, if MT200605 reproduces the Phase II benefit in Phase III, it could become China’s first potentially practice-changing first-line therapy for stroke neuroprotection and provide the first targeted solution for preventing post-stroke AKI. MICOT